Selecta’s Latest Should Have Horizon’s Attention
Research - Selecta’s (SELB) data, presented at EULAR today, look great. Last week we outlined what to look for. Here’s a quick summary of today’s data. SEL-212 … Continue Reading
Premium: Read NowzPremium
Sage’s Big Fat Binary Event is Coming Up
Research - Originally sent to PropThink members on May 3, 2017. Selecta Biosciences (SELB) has been weak since our suggestion two weeks ago, but we still like … Continue Reading
Premium: Read Now
Video: Our April Strategy Webinar is Live
Education - A recording of last night’s webinar is now available! As usual, follow-up questions can be directed to editor@propthink.com. Register And Watch The Video Timestamps below. … Continue Reading
Premium: Read Now
Prepare for Upcoming Events With This Webinar
Research - Our March webinar focused primarily on recent events in the bio/pharma space; some actionable ideas for the next few weeks; and of course, politics (AHCA vote … Continue Reading
Read Now
February Webinar: Your Questions, Answered
Research - A recording of last night’s webinar is ready and available for on-demand viewing. This month focused almost exclusively on your requested topics/companies. Timestamps: 2:00 Macro … Continue Reading
Premium: Read Now
Sage Continues To Diversify: First Oral Depression Data
Long Ideas - The first efficacy data for SAGE-217, the oral follow-on to Sage Therapeutics’ (SAGE) injectable neurosteroid SAGE-547, are out, and they’re encouraging. Recall that SAGE-547 is … Continue Reading
Premium: Read Now
The Well-Worn Path of ERTs
Long Ideas - Last July, Ultragenyx Pharmaceutical (RARE) released positive results from a phase 3 study of its enzyme replacement therapy rhGUS (recombinant human beta-glucuronidase) in the lysosomal … Continue Reading
Read Now